Health Resource Utilization (HRU) and Costs for Metastatic Renal Cell Carcinoma (MRCC) Patients Treated With First-Line (1l) Systemic Therapy in The United States
Nov 1, 2016, 00:00
10.1016/j.jval.2016.09.2332
https://www.valueinhealthjournal.com/article/S1098-3015(16)33698-1/fulltext
Title :
Health Resource Utilization (HRU) and Costs for Metastatic Renal Cell Carcinoma (MRCC) Patients Treated With First-Line (1l) Systemic Therapy in The United States
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)33698-1&doi=10.1016/j.jval.2016.09.2332
First page :
A755
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
2214